Ex vivo Evaluation of Live-MB2 and CX-2 Biotic Strains on Inflammatory and Barrier-Related Biomarkers in a Human Skin Atopic Dermatitis–Like Model Authors: Sejin Cheon, Haeun Lee, Da Yeong Nam, Seokjun Kim, Kyeongeun Kim, Jaeyu Park, Dong-Geol Lee, Chun Ho Park, So Min Kang, Young Mok Heo, Hyun Ho Han, Dong Keon Yon Published: 2026 ABSTRACT AbstractObjectiveAtopic dermatitis (AD) is a chronic inflammatory skin condition characterized by epidermal barrier disruption and immune dysregulation. Live-MB2 and CX-2 were used in an ex vivo human skin AD-like model, which provides a biologically relevant platform for assessing cosmetic ingredients targeting AD-like features.MethodsAn AD-like condition was induced in ex vivo human skin explants by repeated tape stripping followed by 2,4-dinitrochlorobenzene stimulation. Skin tissues were treated with Live-MB2 or CX-2 via topical or dermal exposure. Epidermal thickness, IgE, and filaggrin levels were evaluated using hematoxylin and eosin, immunofluorescence, and Enzyme-Linked Immunosorbent Assay analyses.ResultsTopical application of Live-MB2 and CX-2 significantly reduced epidermal thickness compared with AD-induced controls. IgE levels were significantly reduced, while filaggrin expression indicated a marked increase, indicating barrier recovery. No treatment-related tissue damage was observed.ConclusionLive-MB2 and CX-2 showed favorable effects on inflammatory and barrier-related parameters in an ex vivo human skin AD-like model, supporting their potential application as cosmetic ingredients for sensitive and atopic-prone skin.Keywords: Ex vivo human skin, atopic dermatitis, live biotics, skin barrier, filaggrin, cosmetic ingredients Introduction Atopic dermatitis (AD) is a multifactorial inflammatory skin disorder involving epidermal barrier impairment, immune imbalance, and environmental triggers.1,2 The pathogenesis of AD is largely explained by defects in epidermal barrier function and immune system dysregulation. Notably, mutations and reduced expression of the epidermal barrier protein filaggrin (FLG) decrease the stratum corneum’s water-retention capacity and increase trans epidermal water loss.3 This weakening of the physical barrier facilitates the penetration of allergens and pathogens into the epidermis, thereby triggering an “outside-in” pathogenesis that induces Th2-skewed immune responses and excessive immunoglobulin E (IgE) production.2 In addition to epidermal barrier disruption, AD is strongly associated with type 2 immune inflammation. Key cytokines such as interleukin (IL)-4, IL-13, and IL-31, along with epithelial mediators including thymic stromal lymphopoietin (TSLP), contribute to pruritus, inflammation, and further deterioration of skin barrier function.4,5 Recent studies have shown that the skin of patients with AD exhibits a severe reduction in microbial diversity. In particular, the overgrowth of Staphylococcus aureus is closely associated with epidermal barrier damage and the exacerbation of inflammation.6–8 Consequently, topical application of probiotics to restore the skin microbiome and modulate inflammation has emerged as a promising therapeutic strategy. Topical probiotics and microbiome-based ingredients contribute to suppressing harmful bacteria by secreting antimicrobial peptides and regulating the innate immune responses of the epidermis.9 While many topical microbiome interventions currently rely on non-viable bacterial lysates or postbiotics, these inactive derivatives lack the dynamic ability to colonize, continuously secrete active metabolites, and engage in active host-microbe cross-talk.10,11 Therefore, there is a critical need to investigate the direct immunomodulatory and barrier-restoring effects of viable live biotics on human skin.12–14 Conventional in vitro models using keratinocytes provide mechanistic insights but lack the structural complexity of human skin.15 Compared with conventional two-dimensional keratinocyte models, an ex vivo human skin model preserves native tissue architecture and epidermal-dermal interactions, thereby providing a more biologically relevant platform for evaluating inflammatory and barrier-related changes in human skin. Therefore, this study aimed to investigate the effects of two candidate live biotic strains, Live-MB2 (Epidermidibacterium keratini; previously referred to as EPI-7) and CX-2 (Streptococcus thermophilus), on inflammatory and barrier-related parameters using an ex vivo human skin AD-like model.16,17 Live-MB2 is a skin-derived strain isolated from the human skin microbiome and reported to be more prevalent in younger individuals, with potential relevance to skin homeostasis and microbiome-associated skin function.18 CX-2 is a skin-associated strain with reported potential to support dermal recovery, barrier function, and sensitive-skin normalization.19 Ultimately, we aimed to evaluate their potential application as cosmetic ingredients for sensitive and atopic-prone skin. Methods Human Skin Explants Human skin explants were obtained from the Korea Biomedical Research Institute (KBI) under the approval of the Institutional Review Board (IRB No. 2023–0247 and 2023–0210). Korean females (ages 35, 48, 48, 49 years old) were collected from surgical discards with written informed consent in compliance with the Declaration of Helsinki and relevant national bioethics regulations. Subcutaneous fat was removed, and the skin was sectioned using biopsy punches before culture. The ex vivo skin explants were maintained in a sterile culture system at 37 °C in a 5% CO2 humidified incubator, as previously described in established models. The tissues were placed on Transwell® inserts (Corning Inc., Corning, NY, USA) with the epidermal surface exposed to air to reproduce the physiological air–liquid interface of human skin. The culture medium was replaced every 48 hours. Induction of AD-Like Condition in Human Skin Explants To mimic the structural and immunological characteristics of AD ex vivo, an acute AD-like inflammatory state was induced using a combination of mechanical and chemical barrier disruption. After allowing the human skin explants to equilibrate in an air-liquid interface culture for 24 hours, the stratum corneum was mechanically disrupted by repeated tape stripping (30 consecutive times) using standard adhesive discs (D-Squame; CuDerm Co., Dallas, TX, USA). Immediately following the mechanical disruption, the skin explants were topically stimulated with 0.001% 2,4-dinitrochlorobenzene dissolved in an appropriate vehicle (eg, acetone and olive oil, 3:1 v/v) to induce a robust allergic inflammatory response. The explants were then incubated at 37°C in a 5% CO2 humidified atmosphere. This short-term induction protocol, followed by a 48-hour treatment period, was designed to model an acute rather than chronic AD-like response. Treatment with Live Biotics E. keratini Live-MB2 and S. thermophilus CX-2 strains were obtained from the COSMAX Microbiome Bank (Seongnam, South Korea) and had been previously identified by 16S rRNA sequencing. For inoculum preparation, a single colony grown on an agar plate was inoculated into seed culture medium, followed by a 1% secondary inoculation and further cultivation. Live-MB2 and CX-2 were cultured into Tryptic Soy Broth (TSB; MB Cell, Seoul, South Korea) and de Man, Rogosa and Sharpe broth (MRS broth; MB Cell), respectively, and cultured at 37°C for 48 hours. Following incubation, the bacterial cells were harvested by centrifugation at 15,000 rpm for 3 minutes. The supernatants were carefully discarded, and the remaining cell pellets were washed twice with phosphate-buffered saline (PBS) to remove any residual culture media. The washed bacterial cells were then resuspended in PBS for subsequent ex vivo experiments. Bacterial concentration was determined by serial dilution plating (10−3, 10−4, and 10−5), and CFU/mL was calculated using plates within the countable colony range. Following acute AD induction, Live-MB2 and CX-2 were applied to the skin explants either by topical (epidermal) application or by dermal exposure via the culture medium at a designated concentration for each treatment group. The explants were cultured for an additional 48 hours prior to harvest. Experimental Design Skin explants obtained from four independent donors were allocated across all experimental conditions after induction of an acute AD-like state. A total of 11 experimental groups were established: an untreated control (without AD-like induction), a negative control (with AD-like induction), three vehicle-control groups, three Live-MB2 treatment groups, and three CX-2 treatment groups. For each strain, treatment conditions comprised 1×106 CFU/mL applied via the dermal-side culture medium, 1×103 CFU/mL applied via the dermal-side culture medium, and 1×106 CFU/mL applied topically to the epidermal surface, with corresponding vehicle-control conditions. Each donor contributed one skin punch to each of the 11 groups; therefore, each experimental group contained four explants (n = 4 biological replicates, one explant per donor). This donor-matched allocation ensured that tissues from all four donors were represented across all experimental conditions and minimized donor-dependent bias. Hematoxylin and Eosin (H&E) Staining To assess morphological changes and epidermal thickness, the harvested tissue samples were immediately fixed in 4% paraformaldehyde for 24 hours and embedded in paraffin blocks. The blocks were sectioned into 4–5 μm thick slices using a microtome. After deparaffinization and rehydration, the sections were stained with hematoxylin and eosin (H&E) according to standard protocols. Histological images were captured using a light microscope (original magnification×100). Epidermal thickness was quantitatively measured from the granular layer to the basal layer using image analysis software (ImageJ; National Institutes of Health, Bethesda, MD, USA). For each explant, measurements were obtained from three randomly selected fields, and the mean value was used for analysis. Enzyme-Linked Immunosorbent Assay (ELISA) for IgE and FLG Quantification To quantify specific protein levels, the skin tissues were homogenized in RIPA lysis buffer supplemented with a protease and phosphatase inhibitor cocktail. The lysates were centrifuged at 12,000 rpm for 15 minutes at 4°C, and the supernatants were collected. Total protein concentration was determined using a BCA Protein Assay Kit. The levels of IgE and FLG in the tissue lysates were then measured using commercially available human-specific ELISA kits strictly following the manufacturer’s instructions. The optical density was read at 450 nm using a microplate reader. Each sample was assayed in duplicate, and the mean value was used for analysis. The mean of the duplicate wells was treated as a single technical measurement for each donor-derived explant. For IgE quantification, one donor-derived sample produced no detectable signal and was therefore excluded from the IgE analysis, resulting in n = 3 biological replicates for this endpoint; all other endpoints included n = 4 biological replicates. Immunofluorescence (IF) Staining For the spatial localization and expression analysis of FLG, tissue sections were deparaffinized and subjected to heat-induced epitope retrieval using a citrate buffer (pH 6.0). Sections were blocked with 5% bovine serum albumin for 1 hour at room temperature to prevent non-specific binding. Subsequently, the sections were incubated overnight at 4°C with a primary antibody targeting human FLG. After washing, sections were incubated with a fluorophore-conjugated secondary antibody for 1 hour in the dark. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole. Fluorescence images were obtained using a fluorescence microscope (original magnification ×100). For each explant, three representative fields were analyzed under identical imaging conditions, and the mean signal intensity was used for analysis. Statistical Analysis Unless otherwise specified, analyses were performed using four independent biological replicates (n = 4; one explant per donor per experimental condition). The IgE analysis included three biological replicates (n = 3) because one donor-derived sample yielded no detectable signal. Quantitative data are expressed as the mean ± standard error of the mean (SEM). Statistical analyses were performed using GraphPad Prism software (GraphPad Software, San Diego, CA, USA). The normal distribution of the data was assessed, and statistical significance was determined using one-way analysis of variance followed by an appropriate post-hoc test (Tukey’s or Dunnett’s multiple comparisons test) or paired Student’s t-test for two-group comparisons. A two-sided p-value of less than 0.05 was considered statistically significant. Results Tissue Safety and Epidermal Thickness No treatment-related tissue damage was observed, indicating the safety of the live biotics on human tissue (Figure 1). In the AD-induced control group, epidermal thickness increased markedly to 112.27 μm compared with 56.87 μm in the untreated control group. However, this AD-induced hyperproliferation was significantly reduced following topical application of 41.15% in the Live-MB2 (epidermal thickness, 66.07 μm) and 47.42% in the CX-2 group (59.04 μm) compared with the AD-induced control group, restoring the tissue closer to a normal state (Figure 2). Representative histological images and skin safety evaluation in an ex vivo atopic-like skin model. Cross-sections of human skin explants from a 35-year-old South Korean female donor were visualized via H&E staining (original magnification × 100). (1) Untreated control (without atopy induction); (2) Negative control (with atopy induction); (3–5) Vehicle-treated groups; (6–8) Live-MB2 treated groups; (9–11) CX-2 treated groups. Symbols indicate the presence (+) or absence (−) of the listed condition or treatment. Scale bar = 100 μm. Abbreviation: H&E, hematoxylin and eosin. Epidermal thickness analysis in an ex vivo atopic dermatitis-like skin model. Mean epidermal thickness was quantified using ImageJ software from cross-sections of human skin explants. Topical application of Live-MB2 and CX-2 significantly attenuated the inflammation-induced increase in epidermal thickness compared to the negative control. Data are expressed as mean ± SEM (n = 4 donors). *p < 0.05, **p < 0.01 vs negative control. Abbreviation: SEM, standard error of the mean. Inflammatory and Barrier Markers To evaluate the impact on allergic responses, IgE protein expression levels were analyzed. (Figure 3) Both topically treated groups showed a significant decrease in IgE protein expression compared to the AD-induced control group (IgE, 434.58 pg/mL), with decreases of 48.00% in the Live-MB2 (225.99 pg/mL) and 53.12% in the CX-2 group (203.72 pg/mL). Quantitative analysis of IgE protein expression in an ex vivo atopic dermatitis-like skin model. IgE levels were measured in tissue lysates using ELISA. Treatment with Live-MB2 and CX-2 suppressed the inflammation-induced elevation of IgE levels. Data are expressed as mean ± SEM (n = 3 donors). *p < 0.05, **p < 0.01 vs negative control. Abbreviation: SEM, standard error of the mean. Furthermore, analyses were conducted to observe changes in FLG, a critical marker for physical skin barrier integrity. (Figures 4 and 5) While FLG fluorescence area plummeted in the AD-induced control group due to barrier disruption (FLG fluorescence area, 0.94%), IF analysis showed a marked recovery in both topically treated groups, including Live-MB2 (8.77%) and CX-2 group (17.16%). Consistent findings were observed in the analysis of FLG protein expression. (Figure 6) Compared to the AD-induced control group (FLG, 142.60 pg/mL), FLG protein levels were higher in both the Live-MB2 (231.73 pg/mL) and CX-2 (298.04 pg/mL) groups. Notably, CX-2 significantly promoted the quantitative recovery of FLG protein expression (p < 0.05). Representative immunofluorescence images of FLG in an ex vivo atopic-like skin model. Cross-sections of human skin from a 35-year-old South Korean female donor were analyzed (original magnification × 200). FLG is visualized in green; nuclei are counterstained with DAPI (blue). (1) Untreated control (without atopy induction); (2) Negative control (with atopy induction); (3–5) Vehicle-treated groups; (6–8) Live-MB2 treated groups; (9–11) CX-2 treated groups. (8) and (11) show marked recovery of FLG intensity and continuity. Symbols indicate the presence (+) or absence (−) of the listed condition or treatment. Scale bar = 50 μm. Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; FLG, filaggrin. Quantitative analysis of FLG fluorescence area in an ex vivo atopic dermatitis-like skin model. FLG-positive fluorescence area was quantified as a percentage relative to the total DAPI-stained nuclear area using ImageJ. Topical application of Live-MB2 and CX-2 significantly increased FLG expression. Data are expressed as mean ± SEM (n = 4 donors). **p < 0.01 vs negative control. Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; FLG, filaggrin; SEM, standard error of the mean. Quantitative analysis of FLG protein expression in an ex vivo atopic dermatitis-like skin model. FLG protein concentrations were measured after treatment. Topical application of CX-2 significantly promoted the recovery of FLG levels. Data are expressed as mean ± SEM (n = 4 donors). *p < 0.05 vs negative control. Abbreviations: FLG, filaggrin; SEM, standard error of the mean. Discussion Key Findings This study evaluated the effects of novel probiotic ingredients, including Live-MB2 and CX-2, utilizing an ex vivo human skin AD-like model. Live-MB2 and CX-2 treatment was not associated with tissue damage. Epidermal thickness was significantly reduced in both topically treated groups. IgE protein expression significantly reduced in both the topically treated Live-MB2 and CX-2 groups compared to AD-induced control group. FLG protein expression significantly recovered in the topical CX-2 group. The novelty of the present study lies in the evaluation of these two candidates live biotic strains in a human ex vivo AD-like skin model that preserves native tissue architecture and epidermal–dermal interactions. These findings suggest that Live-MB2 and CX-2 may contribute to barrier-repairing and anti-inflammatory functions, without evidence of overt tissue damage under the present experimental conditions. Plausible Underlying Mechanisms The reduction in epidermal thickness and the enhancement of FLG expression observed in this study suggest that Live-MB2 and CX-2 may contribute to barrier-related improvement in AD-like skin. A pathological hallmark of AD is the overexpression of Th2 cytokines (eg, IL-4, IL-13), which inhibits the synthesis of FLG in the epidermis, thereby contributing to barrier dysfunction and inflammation.20–22 The decreasing trend in IgE levels and the recovery of FLG expression, particularly in the topical CX-2 group, suggest that live biotic treatment may influence processes associated with barrier impairment and inflammatory dysregulation in AD-like skin, although the underlying molecular mechanisms were not directly examined in the present study.4 The observed reductions in epidermal thickness and the enhancement of FLG expression further support the potential relevance of both Live-MB2 and CX-2 to barrier-related changes in AD-like skin. Topically applied live biotics may interact with keratinocytes at the skin surface to induce local immune tolerance or stimulate the production of essential skin barrier proteins.23,24 In this regard, previous studies reported that metabolites and antimicrobial peptides secreted by skin commensal bacteria inhibit inflammatory microbes and protect the physical barrier.6,25,26 These findings are consistent with previous reports on the efficacy of topical microbiome modulators. Comparisons with Previous Studies This study utilized an ex vivo model to evaluate probiotic ingredients. Compared with conventional 2D in vitro keratinocyte cultures, the ex vivo human skin model provides a more physiologically relevant platform by preserving native tissue architecture and epidermal–dermal interactions.16,17 Within this experimental context, the observed effects of Live-MB2 and CX-2 support their potential relevance to barrier-related and inflammatory changes in AD-like skin. Although conventional immunosuppressive therapies, including topical corticosteroids, are widely used in AD management, the present findings should be interpreted cautiously because this study was performed in an ex vivo model without a positive control or direct mechanistic analyses.27,28 Accordingly, Live-MB2 and CX-2 may be considered candidate live biotic ingredients with potential relevance to skin barrier- and inflammation-related applications, rather than established therapeutic alternatives at this stage. The observed restoration of epidermal barrier-related readouts by CX-2 and Live-MB2, together with the absence of overt tissue damage under the present experimental conditions, supports their potential relevance to microbiome-based approaches for AD-like skin.4 Beyond their mechanistic benefits, the direct topical application of live biotics represents a complementary strategy from transient symptom management to proactive skin ecosystem restoration.13,14 Because viable strains like Live-MB2 and CX-2 can continuously secrete functional metabolites and dynamically engage in host-microbe cross-talk, they could offer sustained barrier-enhancing efficacy compared to non-viable postbiotics.29 Practically, these findings underscore the high industrial and medical applicability of live biotics as next-generation dermo cosmetics (cosmeceuticals) and adjunctive treatments in clinical dermatology for sensitive and atopic-prone skin.30 Strengths and Limitations There are several limitations to our study. First, donor-to-donor variation inherent to ex vivo human skin AD-like models may introduce variability in outcomes attributable to intrinsic genetic differences across donated skin tissues.31 In particular, donor-specific characteristics such as sex, age, and ethnicity represent important variables that should be carefully considered in future investigations to elucidate differential immune responses in the skin.31,32 In this study, tissue samples were collected from four donors of varying ages, with deliberate emphasis placed on ensuring donor diversity. Nevertheless, further studies incorporating a larger donor cohort will be required to comprehensively assess the potential confounding influence of sex and ethnicity on the observed outcomes. In addition, no positive control, such as an established AD treatment or a previously validated probiotic/postbiotic formulation, was included in the present study; therefore, the relative efficacy of Live-MB2 and CX-2 could not be determined. Second, the immune responses observed in ex vivo human skin AD-like models are inherently limited in their ability to reflect in vivo conditions, particularly because these systems lack systemic immune responses, circulating immune cells, vascular components, and long-term microbiome interactions that are relevant to AD pathophysiology.31 Moreover, the current study primarily evaluated phenotypic endpoints, including epidermal thickness, IgE, and FLG-related readouts, and did not directly assess key AD-associated inflammatory mediators such as IL-4, IL-13, IL-31, TSLP, or related signaling mechanisms. Future investigations employing randomized controlled trials in in vivo settings would be warranted to further validate and extend the explanatory power of the findings reported in the present study.33 Although the strains used in this study had been previously identified by 16S rRNA sequencing, no additional sequencing was performed immediately before the experiment. In addition, viability was not re-confirmed immediately prior to tissue application, and stability during the experimental period was not separately evaluated. Despite these limitations, our study has important strengths. This study provides the first comprehensive ex vivo assessment of the effects of two novel live biotics, Live-MB2 and CX-2, on AD-induced skin. While conventional in vitro models utilizing keratinocytes offer valuable mechanistic insights, they inherently lack the cellular complexity of intact human skin.15 Accordingly, the present findings should be interpreted as preliminary ex vivo evidence supporting the potential of these strains in skin barrier- and inflammation-related applications. Our findings serve as a foundational ex vivo evidence base to inform the development of candidate active ingredients for medical-grade skincare applications. Conclusion Live-MB2 and CX-2 demonstrated promising effects on inflammatory- and barrier-related parameters in an ex vivo human skin AD-like model. These findings provide preliminary ex vivo evidence supporting the potential of live biotics as microbiome-based candidate active ingredients for sensitive and atopic-prone skin. In particular, the observed changes in epidermal thickness, IgE, and FLG-related readouts support the further evaluation of these strains in skin barrier- and inflammation-related applications. This study also highlights the value of ex vivo human skin models as biologically relevant platforms for the preclinical assessment of candidate microbiome-based ingredients. Further in vivo and clinical studies are warranted to confirm their long-term efficacy, safety, and clinical relevance. Funding Statement This work was supported by the Institute of Information & Communications Technology Planning & Evaluation (IITP) grant funded by the Korea government (IITP-2026-RS-2026-25617111). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Ethics Approval and Informed Consent Human skin explants were obtained from the Korea Biomedical Research Institute under the approval of the Institutional Review Board (IRB No. 2023-0247 and 2023-0210). Korean females (ages 35, 48, 48, 49 years old) were collected from surgical discards with written informed consent in compliance with the Declaration of Helsinki and relevant national bioethics regulations. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. S.C., H.L., D.Y.N. and S.K. contributed equally as first authors. S.M.K., Y.M.H., H.H.H. and D.K.Y. contributed equally as corresponding authors. Disclosure Dr Young Mok Heo reports Support for the manuscript from COSMAX BTI, during the conduct of the study. The authors declare no conflict of interest. References